Brinzolamide

Bibliography

• American Academy of Ophthalmology. Basic and clinical science course: Primary open-angle glaucoma. San Francisco, CA: American Academy of Ophthalmology; 2002
   Google Scholar
• Zeyen TG, Caprioli J. Progression of disc and field damage in early glaucoma. Arch Ophthalmol 1993;111:62-5
   PubMed Web of Science ®Google Scholar
• Pederson JE, Anderson DR. The mode of progressive disc cupping in ocular hypertension and glaucoma. Arch Ophthalmol 1980;98:490-5
   PubMed Web of Science ®Google Scholar
• European Glaucoma Society. Terminology and Guidelines for Glaucoma 2003. 2nd edition. Available from: http://www.eugs.org/fullbook/eng.pdf [Last accessed 10 February 2008].
   Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al.; The Ocular Hypertension Treatment Study. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79
   PubMed Web of Science ®Google Scholar
• Cvetkvic RS, Perry CM. Brizolamide. A review of its use in the management of Primari open-angle glaucoma and ocular hypertension. Drug Aging 2003;20:919-47
   PubMed Web of Science ®Google Scholar
• Shoji N. Brinzolamide: efficacy, safety and its role in the management of glaucoma. Expert Rev Ophthalmol 2007;2:695-704
   Google Scholar
• Maren TH. Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol Rev 1967;47:595-781
   PubMed Web of Science ®Google Scholar
• Kaur IP, Smitha R, Deepika A, Kapil M. Acetazolamide: future perspective in topical glaucoma therapeutics. Int J Pharm 2002;248:1-14
   PubMed Web of Science ®Google Scholar
• DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol 2000;44(Suppl 2):S119-29
   PubMed Web of Science ®Google Scholar
• March WF, Ochsner KI. The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. Am J Ophthalmol 2000;129:136-43
   PubMed Web of Science ®Google Scholar
• Toris CB, Zhan GL, McLaughlin MA. Effects of brinzolamide on aqueous humor dynamics in monkeys and rabbits. J Ocul Pharmacol Ther 2003;19:397-404
   PubMedGoogle Scholar
• Ingram CJ, Brubaker RF. Effect of brinzolamide and dorzolamide on aqueous humor flow in human eyes. Am J Ophthalmol 1999;128:292-6
   PubMed Web of Science ®Google Scholar
• Budenz DL, Anderson DR, Feuer WJ, et al. Detection and prognostic significance of optic disc hemorrhages during the Ocular Hypertension Treatment Study. Ophthalmology 2006;113:2137-43
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003;121:48-56
   PubMed Web of Science ®Google Scholar
• Tielsch JM, Katz J, Sommer A, et al. Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. Arch Ophthalmol 1995;113:216-21
   PubMed Web of Science ®Google Scholar
• Bonomi L, Marchini G, Maraffa M, et al. Vascular risk factors for primary open angle glaucoma. Ophthalmology 2000;107:1287-93
   PubMed Web of Science ®Google Scholar
• Barnes GE, Li B, Dean T, Chandler ML. Increased optic nerve head blood flow after 1 week of twice daily topical brinzolamide treatment in Dutch-belted rabbits. Surv Ophthalmol 2000;44(Suppl 2):S131-40
   Google Scholar
• Sampaolesi J, Tosi J, Darchuk V, et al. Antiglaucomatous drugs effects on optic nerve head flow: design, baseline and preliminary report. Int Ophthalmol 2001;23:359-67
   PubMedGoogle Scholar
• Siesky B, Lin T, Kagemann L, et al. Comparison of three months treatment with dorzolamide and brinzolamide on perfusion pressures in primary open angle glaucoma patients. Paper presented at the International Symposium on Ocular Pharmacology and Therapeutics. Berlin; April 2006
   Google Scholar
• Iester M, Altieri M, Michelson G, et al. Retinal peripapillary blood flow before and after topical brinzolamide. Ophthalmologica 2003;218:390-6
   Web of Science ®Google Scholar
• Kaup M, Plange N, Niegel M, et al. Effects of brinzolamide on ocular haemodynamics in healthy volunteers. Br J Ophthalmol 2004;88:257-62
   PubMed Web of Science ®Google Scholar
• Kothy P, Hollo G. Does glaucoma medication influence the diameter of the retinal arteriole in the human eyes? (A pilot study using the retinal vessel analyser). Aca Phisiol Hungarica 2001;88:281-92
   PubMedGoogle Scholar
• Konowal A, Morrison JC, Brown SVL, et al. Irreversible corneal decompansation in patients treated with topical dorzolamide. Am J Ophthalmol 1999;127:403-6
   PubMed Web of Science ®Google Scholar
• Adamson I. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol 1999;128:774-5
   PubMedGoogle Scholar
• Zhao JC, Chen T. Brinzolamide induced reversible corneal decompensation. Br J Ophthalmol 2005;89:389-90
   PubMed Web of Science ®Google Scholar
• Wang TH, Huang JY, Hung PT, et al. Ocular hypotensive effect and safety of brinzolamide ophthalmic solution in open angle glaucoma patients. J Formos Med Assoc 2004;103:369-73
   PubMed Web of Science ®Google Scholar
• Silver LH. Dose-response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt). Brinzolamide Dose-Response Study Group. Surv Ophthalmol 2000;44(Suppl 2):S147-53
   Web of Science ®Google Scholar
• Sall K. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group. Surv Ophthalmol 2000;44(Suppl 2):S155-62
   PubMed Web of Science ®Google Scholar
• Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol 1998;126:400-8
   PubMed Web of Science ®Google Scholar
• Shin D. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy. Surv Ophthalmol 2000;44(Suppl 2):S163-8
   PubMed Web of Science ®Google Scholar
• Michaud JE, Friren B. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:235-43
   PubMed Web of Science ®Google Scholar
• Van der Valk R, Webers CAB, Schouten JSAG, et al. Intraoculare pressure-lowering effects of all commonly used glaucoma drugs. A meta-analysis of randomized clinical trials. Ophthalmology 2005;112:1177-85
   PubMed Web of Science ®Google Scholar
• Ermis SS, Ozturk F, Inan UU. Comparing the effects of travoprost and brinzolamide on intraocular pressure after phacoemulfication. Eye 2005;19:303-7
   PubMedGoogle Scholar
• Dayanir V, Ozcura F, Kir E, et al. Medical control of intraocular pressure after phacoemulsification. J Cat Refract Surg 2005;31:484-8
   PubMedGoogle Scholar
• Shoji N, Ogata H, Suyama H, et al. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study. Curr Med Res Opin 2005;21:503-8
   PubMed Web of Science ®Google Scholar
• Franks W. Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin 2006;22:1643-9
   PubMed Web of Science ®Google Scholar
• Hollo G, Chiselita D, Petkova N, et al. The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. Eur J Ophthalmol 2006;16:816-23
   PubMed Web of Science ®Google Scholar
• Nakamoto K, Yasuda N. Effect of concomitant use of latanoprost and brinzolamide on 24-hour variation of IOP in normal-tension glaucoma. J Glaucoma 2007;16:352-7
   PubMed Web of Science ®Google Scholar
• Feldman RM, Tanna AP, Gross RL, et al. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%. Ophthalmology 2007;114:1248-54
   PubMed Web of Science ®Google Scholar
• Reis R, Queiroz CF, Santos LC, et al. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Clin Ther 2006;28:552-9
   PubMed Web of Science ®Google Scholar
• Martinez-de-la-Casa JM, Castillo A, Garcia-Feijoo J, et al. Concomitant administration of travoprost and brinzolamide versus fixed latanoprost/timolol combined therapy: three-month comparison of efficacy and safety. Curr Med Res Opin 2004;20:1333-9
   PubMed Web of Science ®Google Scholar
• Seong GJ, Lee SC, Lee JH, et al. Comparison of intraocular pressure lowering efficacy and side effects of 2% dorzolamide and 1% brinzolamide. Ophthalmologica 2001;215:188-91
   PubMed Web of Science ®Google Scholar
• Stewart WC, Day DG, Stewart JA, et al. Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open angle glaucoma and ocular hypertension subjects. Eye 2004;18:905-10
   PubMed Web of Science ®Google Scholar
• Tsukamoto H, Noma H, Matsuyama S, et al. The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta-blocker in patients with glaucoma. J Ocul Pharmacol Ther 2005;21:170-3
   PubMed Web of Science ®Google Scholar
• Tsukamoto H, Noma H, Mukai S, et al. The efficacy and ocular discomfort of substituting brinzolamide for dorzolamide in combination therapy with latanoprost, timolol, and dorzolamide. J Ocul Pharmacol Ther 2005;21:395-9
   PubMed Web of Science ®Google Scholar
• Menon GJ, Vernon SA. Topical brinzolamide and metabolic acidosis. Br J Ophthalmol 2006;90:247-8
   PubMed Web of Science ®Google Scholar
• Silver LH. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol 2000;44(Suppl 2):S141-5
   PubMed Web of Science ®Google Scholar
• Barnebey H, Kwok SY. Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther 2000;22:1204-12
   PubMed Web of Science ®Google Scholar
• Herkel U, Pfeiffer N. Update on topical carbonic anydrase inhibitors. Curr Opin Ophthalmol 2001;12:88-93
   PubMedGoogle Scholar
• Galassi F, Nuzzaci G, Sodi A, et al. Color Doppler imaging in evaluation of optic nerve blood supply in normal and glaucomatous subjects. Int Ophthalmol 1992;16:273-6
   PubMedGoogle Scholar
• Gherghel D, Orgul S, Gugleta K, et al. Relation between ocular perfusion and retrobulbar blood flow in patients with glaucoma with progressive damage. Am J Ophthalmol 2000;130:597-605
   PubMed Web of Science ®Google Scholar
• Harris A, Arend O, Kagemann L, et al. Dorzolamide, visual function and ocular hemodynamics in normal tension glaucoma. J Ocul Pharm Ther 1999;15:189-97
   PubMed Web of Science ®Google Scholar
• Harris A, Arend O, Arend S, Martin B. Effects of topical dorzolamide on retinal and retrobulbar hemodynamics. Acta Opthalmol Scand 1996;74:569-72
   PubMedGoogle Scholar
• Carlsson AM, Chauhan BC, Lee AA, LeBlanc RP. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension. Am J Ophthalmol 2000;129:297-301
   PubMed Web of Science ®Google Scholar
• Barnes GE, Wilhelm F, Schoch C. Increased optic nerve head blood flow after 1 week of twice daily topical brinzolamide treatment in Dutch-belted rabbits. Surv Ophthalmol 2000;44:S131-40
   Google Scholar
• Sponsel WE, Shipman DL. The role of blood gases in ocular perfusion. In: Ocular Blood Flow, Volume 3. Drance S, Chauhan B, editors. Amsterdam: Kugler; 1997
   Google Scholar
• Hauge A, Nicolaysen G, Thoresen M. Acute effects of acetazolamide on cerebral blood flow in man. Acta Physiol Scand 1983;117:233-9
   PubMedGoogle Scholar
• Ringelstein EB, Van Eyck S, Mertens I. Evaluation of cerebral vasomotor reactivity by various vasodilating stimuli: comparison of CO2 to acetazolamide. J Cereb Blood Flow 1992;12:162-8
   PubMed Web of Science ®Google Scholar
• Severinghaus JW, Cotev S. Carbonic acidosis and cerebral vasodilatation after diamox. Scand J Clin Lab Invest 1968;22:1E
   PubMedGoogle Scholar
• Volstrup S, Henriken L, Paulson DB. Effect of acetazolamide on cerebral blood flow and cerebral metabolic rate oxigen. J Clin Invest 1984;74:1634-9
   PubMedGoogle Scholar
• Faraci FM, Heistad DD, Mayham WG, et al. Role of larger arteries in regulation of blood flow to the brain stem in cats. J Physiol 1987;387:112-5
   Web of Science ®Google Scholar
• Costa VP, Harris A, Stefansson E, et al. The effects of antiglaucomatous and systemic medications on ocular blood flow. Progr Retin Eye Res 2003;22:769-805
   PubMed Web of Science ®Google Scholar